{"id":"NCT01290731","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy","officialTitle":"A Phase III, Open-label Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Genotype 1, Hepatitis C-infected Subjects Who Relapsed After Previous IFN-based Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-01","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2011-02-07","resultsPosted":"2014-02-04","lastUpdate":"2014-02-04"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Pegylated interferon (pegIFN alpha-2a)","otherNames":["PEGASYS"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["COPEGUS"]}],"arms":[{"label":"TMC435 100 mg 12 Wks + PR24/48","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNÎ±-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who relapsed after previous interferon (IFN)-based therapy in Japan.","primaryOutcome":{"measure":"The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)","timeFrame":"Week 36 or 60","effectByArm":[{"arm":"TMC435 100 mg 12 Wks + PR24/48","deltaMin":95.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":49},"commonTop":["Pyrexia","Neutrophil count decreased","White blood cell count decreased","Headache","Malaise"]}}